Physician profile
Sandra Dempsey
NPI 1124124870
$10,083.54
in general payments reported to CMS, 2019-2025
57 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,943 · 2020: $1,781 · 2021: $1,825 · 2022: $1,368 · 2023: $1,391 · 2024: $1,127 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.99 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,525.18 | 2019-2022 | |
| Lilly USA, LLC | $1,206.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,188.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $515.76 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $505.98 | 2019-2024 | |
| Dexcom, INC. | $427.80 | 2019-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $420.60 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $314.86 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $312.09 | 2019-2024 | Synthroid |
| Esperion Therapeutics, INC. | $273.30 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $233.01 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $195.05 | 2021-2025 | Isturisa, Signifor Lar |
| Amneal Pharmaceuticals LLC | $176.05 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $174.37 | 2021-2024 | |
| Horizon Therapeutics Plc | $172.33 | 2021-2023 | Tepezza |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Dempsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.